Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,765 across all filing types
Latest filing 2021-05-10 Call Transcript
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) informing about a scheduled teleconference (conference call) with investors and analysts to discuss the financial performance for the quarter and year ended 31st March 2021. It provides dial-in details for the call but does not contain any financial data or results itself. The document is an announcement of a conference call event, not the transcript or financial report. Therefore, it fits the category of a Call Transcript announcement or notification. Since it is an announcement of the call, the best fitting category is Call Transcript (CT).
2021-05-10 English
Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, it is hereby informed that India Ratings and Research Private Limited has revised outlook ....
Capital/Financing Update Classification · 95% confidence The document is an official communication dated May 6, 2021, from Torrent Pharmaceuticals Limited to BSE Limited, informing about a credit rating update by India Ratings and Research Private Limited. It details the revision of the outlook from 'Stable' to 'Positive' and affirms the long-term issuer rating at IND AA. The document includes detailed analysis of the company's financial performance, market presence, regulatory risks, and rating sensitivities. It also contains financial summaries, rating history, and annexures related to the rated instruments. The content is focused on credit rating updates and financial health assessment rather than a full annual or quarterly financial report. It is not a full audit report, earnings release, or management discussion and analysis. The document is a regulatory announcement about credit rating changes, which fits best under the category of Capital/Financing Update (CAP), as it relates to the company's credit rating and debt instruments. The document length is substantial (15,000 characters), indicating it is not a mere announcement of a report but a detailed update. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-05-06 English
Credit Rating
Capital/Financing Update Classification · 95% confidence The document is a detailed communication from Torrent Pharmaceuticals Limited regarding a credit rating update by India Ratings and Research Private Limited. It includes specifics about rating revisions, outlook changes, instrument types, financial performance, and company profile. The content focuses on credit rating affirmation and outlook revision, with detailed financial and operational analysis. It is not a full annual or interim financial report, nor is it a brief announcement or a certification. The document is primarily a credit rating update and analysis, which fits best under the category of Capital/Financing Update (CAP), as it relates to the company's credit rating and financial instruments. The document length (15,000 characters) and detailed financial data support this classification with high confidence.
2021-05-06 English
Board Meeting — Financial Results/Dividend/Fund Raising
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) informing about the date of a forthcoming Board Meeting. It mentions that the Board will consider approving the Audited Financial Results for the fiscal year ended 31-Mar-21, payment of final dividend, and potential fundraising resolutions. The letter is dated 28 April 2021 and is an intimation under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The document does not contain the financial results themselves, nor detailed financial data, but is a notice about the Board Meeting where such matters will be discussed. The document length is short (1762 characters) and it is an announcement of an upcoming event rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and notification to the exchange about the Board Meeting date and agenda.
2021-04-28 English
Torrent Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors will be held on May 18, 2021, inter alia, to consider and approve the Audited Financial Results of ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchanges (BSE and NSE) informing them about the date of an upcoming Board Meeting. The letter states that the Board Meeting will consider approving the Audited Financial Results for the fiscal year ended 31-Mar-21, payment of final dividend, and potential fundraising resolutions. This is a notification of a scheduled Board Meeting and the agenda items to be discussed, not the actual financial results or reports themselves. The document is short (1762 characters) and serves as an announcement rather than a full report. Therefore, it fits the category of Regulatory Filings (RNS) as a general regulatory announcement under SEBI Listing Regulations, specifically Regulation 29, which requires intimation of Board Meetings.
2021-04-28 English
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2021 ,inter alia, to consider and approve We would like to inform ....
Board/Management Information Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) informing about the date of a forthcoming Board Meeting. It mentions that the Board will consider approving the Audited Financial Results for the fiscal year ended 31-Mar-21, payment of final dividend, and potential fundraising resolutions. The document is dated 28 April 2021 and is an intimation under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The document is short (1762 characters) and serves as a notice of a Board Meeting rather than the actual financial results or reports. Therefore, it is an announcement related to corporate governance and board activities, specifically a Board/Management Information filing.
2021-04-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.